Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antithrombotic strategy in stroke.

M G Bousser1

  • 1Service de Neurologie, Hĵpital Lariboisière, Paris, France. marie-germaine.bousser@lrb.ap-hop-paris.fr

Thrombosis and Haemostasis
|August 7, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CADASIL: yesterday, today, tomorrow.

European journal of neurology·2020
Same author

Shunting in acute cerebral venous thrombosis: a systematic review.

Cerebrovascular diseases (Basel, Switzerland)·2013
Same author

Safety of lumbar puncture in patients with cerebral venous thrombosis.

European journal of neurology·2013
Same author

Neonatal cerebral venous thrombosis: le debut.

The Journal of pediatrics·2010
Same author

Verbal memory impairment in subcortical ischemic vascular disease: a descriptive analysis in CADASIL.

Neurobiology of aging·2010
Same author

Do patients have any special medical or rehabilitation difficulties after a craniectomy for malignant cerebral infarction during their hospitalization in a physical medicine and rehabilitation department?

Annals of physical and rehabilitation medicine·2010
Same journal

Anti-TFPI Single-Domain Antibodies: Novel Rebalancing Therapies for Hemophilia and Other Rare Bleeding Disorders.

Thrombosis and haemostasis·2026
Same journal

The Interaction of Fibrin with Endothelial Cell Receptor N-Cadherin Promotes Fibrin-Dependent Angiogenesis.

Thrombosis and haemostasis·2026
Same journal

Antiphospholipid Antibodies and Atrial Fibrillation: Clinical Implications and the TaPL AF Study Design.

Thrombosis and haemostasis·2026
Same journal

Prasugrel vs. Ticagrelor: Can TUXEDO-2 Settle the Debate?

Thrombosis and haemostasis·2026
Same journal

Methylglyoxal Promotes RBC-Driven Procoagulant Activity and Venous Thrombosis under Diabetes-Relevant Conditions.

Thrombosis and haemostasis·2026
Same journal

Management of Inferior Vena Cava Thrombosis: Guidance from the Italian Society for the Study of Haemostasis and Thrombosis.

Thrombosis and haemostasis·2026
See all related articles

Evidence-based antithrombotic strategies are crucial for stroke prevention and treatment. Aspirin is recommended for atherothrombotic stroke and acute treatment, while anticoagulants are used for cardioembolic stroke.

Area of Science:

  • Neurology
  • Cardiology
  • Pharmacology

Background:

  • Antithrombotic therapy is vital for managing ischemic stroke, but carries a risk of intracranial hemorrhage.
  • Stroke management strategies vary based on etiology and acute treatment options.

Purpose of the Study:

  • To outline evidence-based antithrombotic strategies for stroke prevention and acute treatment.
  • To provide recommendations based on numerous randomized controlled trials.

Main Methods:

  • Review of randomized controlled trials (RCTs) on antithrombotic therapy in stroke.
  • Analysis of treatment strategies based on stroke etiology (atherothrombotic vs. cardioembolic).
  • Evaluation of acute treatment protocols, including intravenous thrombolysis (IV rt-PA) and antiplatelet/anticoagulant use.

Related Experiment Videos

Main Results:

  • Aspirin is the first-choice antiplatelet for atherothrombotic stroke prevention.
  • Oral anticoagulants are recommended for cardioembolic stroke prevention.
  • Intravenous rt-PA is recommended within 3 hours for acute ischemic stroke if criteria are met; otherwise, aspirin is the choice.
  • Low-dose low-molecular-weight heparin (LMWH) may be used with aspirin for immobile patients.
  • High-dose heparin or LMWH lacks efficacy in stroke, except for cerebral venous thrombosis.

Conclusions:

  • Antithrombotic strategies are tailored to stroke type and acute presentation.
  • Careful patient selection and adherence to guidelines are essential for effective and safe stroke treatment.
  • Further research may refine optimal antithrombotic approaches in specific stroke subtypes.